This post was originally published on this site

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) price on Friday, Jun 04, rose 0.56% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $18.1.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

A look at the stock’s price movement, the close in the last trading session was $18, moving within a range at $18.03 and $18.36. The beta value (5-Year monthly) was 0.47 while the PE ratio in trailing twelve months stood at 31.98. Turning to its 52-week performance, $20.51 and $9 were the 52-week high and 52-week low respectively. Overall, VNDA moved 9.17% over the past month.

Vanda Pharmaceuticals Inc.’s market cap currently stands at around $1.03 Billion, with investors looking forward to this quarter’s earnings report slated for Aug 03, 2021- Aug 09, 2021. The company has a Forward Dividend ratio of 0, with its dividend yield at 0%. As such, investors might be keen on a downside in the stock’s price ahead of the scheduled earnings report. Analysts project the company’s earnings per share (EPS) to be $0.14, which has seen fiscal year 2021 EPS growth forecast to increase to $0.61 and about $0.79 for fiscal year 2022. Per the data, EPS growth is expected to be 0.45% for 2021 and 0.3% for the next financial year.

Analysts have a consensus estimate of $69.75 Million for the company’s revenue for the quarter, with a low and high estimate of $68.5 Million and $71Million respectively. The average forecast suggests up to a 12.1% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $282.92 Million, representing a +14% jump on that reported in the last financial year.

Turning to the stock’s technical picture we see that short term indicators suggest on average that VNDA is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.

2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of none analyst(s) rate the stock as a Hold, 2 recommend VNDA as a Buy and none give it an Outperform rating. Meanwhile, none analyst(s) rate the stock as Underperform and none say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.

The technical evaluation for the stock shows the PEG ratio is 0, with VNDA’s current price about 0.06% and 6.44% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 55.9, while 7-day volatility ratio is 2.73% and 3.38% in the 30-day chart. Further, Vanda Pharmaceuticals Inc. (VNDA) has a beta value of 0.47, and an average true range (ATR) of 0.54. Analysts have given the company’s stock an average 52-week price target of $23, forecast between a low of $22 and high of $24. Looking at the price targets, the low is 21.55% off current price level while to achieve the yearly target high, price needs to move +32.6%. Nonetheless, investors will most likely welcome a +27.07% jump to $23 which is the analysts’ median price.

In the market, a comparison of Vanda Pharmaceuticals Inc. (VNDA) and its peers suggest the former has performed considerably better. Data shows VNDA’s intraday price has changed +0.56% in last session and +57.67% over the past year. Comparatively, Bristol-Myers Squibb Company (BMY) has moved +0.22% on the day and only +6.65% in the past 12 months. Looking at another peer, we see that Amgen Inc (AMGN) price has surged 0.47% on the day. However, the stock is 7.23% off its price a year ago. Moreover, Gilead Sciences Inc (GILD) is also up 0.56% in trading on the day while keeping an uptrend of 57.67% over the past year. If we look at the PE ratio, we find that Vanda Pharmaceuticals Inc.’s ratio stands at 31.98 compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 19.61. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.88% and 0.52% respectively in the last trading.

If we refocus on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), historical trading data shows that trading volumes averaged 379.33 Million over the past 10 days and 416.9 Million over the past 3 months. The company’s latest data on shares outstanding shows there are 55.56 Million shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

As per Thomson Reuters, 2.61% of Vanda Pharmaceuticals Inc.’s shares are in the hands of company insiders while institutional holders own 101.65% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.96 Million on May 13, 2021, giving us a short ratio of 14.87. The data shows that as of May 13, 2021 short interest in Vanda Pharmaceuticals Inc. (VNDA) stood at 8.92% of shares outstanding, with shares short dropping from 5.26 Million registered in April. Current price change has pushed the stock +37.75% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VNDA stock continues to rise going into the next quarter.